Related Experiment Video
Updated: Jun 24, 2026
12:24
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
Targeting CD40 in Waldenström's macroglobulinemia
1Oncology Division, Stanford University Medical Center, Stanford, CA 94305, USA.
Clinical Lymphoma & Myeloma
|April 14, 2009
Summary
CD40 is a key target in B-cell cancers. Antibodies targeting CD40 show promise for treating Waldenström
Area of Science:
- Immunology
- Oncology
- Hematology
Background:
- CD40, a TNF receptor family member, is expressed in B-cell malignancies.
- CD40 signaling is crucial for Waldenström's macroglobulinemia (WM) growth and survival.
- CD40 is a common feature in bone marrow infiltrating lymphoplasmacytic cells in WM.
Purpose of the Study:
- To evaluate the potential of CD40-targeted agents in treating Waldenström's macroglobulinemia (WM).
Main Methods:
- Review of preclinical data and clinical trial results for CD40 antibodies (SGN-40 and HCD122).
- Assessment of CD40 expression in WM lymphoplasmacytic cells.
- Analysis of antibody-dependent cellular cytotoxicity (ADCC) mediated by CD40 antibodies.
Main Results:
- CD40 antibodies (SGN-40, HCD122) demonstrate preclinical activity and mediate ADCC.
- Phase I clinical data show CD40 antibodies are well-tolerated with early clinical activity in NHL and MM.
- No immunogenicity observed with CD40-targeted agents.
Conclusions:
- CD40-targeted agents show therapeutic potential in B-cell malignancies.
- Clinical observations support further investigation of CD40-targeted therapies in WM.
